Christian M Madsen1,2,3, Pia R Kamstrup1,2, Anne Langsted1,2,3, Anette Varbo1,2,3, Børge G Nordestgaard1,2,4,3. 1. From the Department of Clinical Biochemistry (C.M.M., P.R.K., A.L., A.V., B.G.N.), Copenhagen University Hospital, Denmark. 2. The Copenhagen General Population Study, Herlev and Gentofte Hospital (C.M.M., P.R.K., A.L., A.V., B.G.N.), Copenhagen University Hospital, Denmark. 3. Faculty of Health and Medical Sciences, University of Copenhagen, Denmark (C.M.M., A.L., A.V., B.G.N.). 4. The Copenhagen City Heart Study, Frederiksberg Hospital (B.G.N.), Copenhagen University Hospital, Denmark.
Abstract
OBJECTIVE: High Lp(a) (lipoprotein[a]) cause cardiovascular disease (CVD) in a primary prevention setting; however, it is debated whether high Lp(a) lead to recurrent CVD events. We tested the latter hypothesis and estimated the Lp(a)-lowering needed for 5 years to reduce CVD events in a secondary prevention setting. Approach and Results: From the CGPS (Copenhagen General Population Study; 2003-2015) of 58 527 individuals with measurements of Lp(a), 2527 aged 20 to 79 with a history of CVD were studied. The primary end point was major adverse cardiovascular event (MACE). We also studied 1115 individuals with CVD from the CCHS (Copenhagen City Heart Study; 1991-1994) and the CIHDS (Copenhagen Ischemic Heart Disease Study; 1991-1993). During a median follow-up of 5 years (range, 0-13), 493 individuals (20%) experienced a MACE in the CGPS. MACE incidence rates per 1000 person-years were 29 (95% CI, 25-34) for individuals with Lp(a)<10 mg/dL, 35 (30-41) for 10 to 49 mg/dL, 42 (34-51) for 50 to 99 mg/dL, and 54 (42-70) for ≥100 mg/dL. Compared with individuals with Lp(a)<10 mg/dL (18 nmol/L), the multifactorially adjusted MACE incidence rate ratios were 1.28 (95% CI, 1.03-1.58) for 10 to 49 mg/dL (18-104 nmol/L), 1.44 (1.12-1.85) for 50 to 99 mg/dL (105-213 nmol/L), and 2.14 (1.57-2.92) for ≥100 mg/dL (214 nmol/L). Independent confirmation was obtained in individuals from the CCHS and CIHDS. To achieve 20% and 40% MACE risk reduction in secondary prevention, we estimated that plasma Lp(a) should be lowered by 50 mg/dL (95% CI, 27-138; 105 nmol/L [55-297]) and 99 mg/dL (95% CI, 54-273; 212 nmol/L [114-592]) for 5 years. CONCLUSIONS: High concentrations of Lp(a) are associated with high risk of recurrent CVD in individuals from the general population. This study suggests that Lp(a)-lowering by 50 mg/dL (105 nmol/L) short-term (ie, 5 years) may reduce CVD by 20% in a secondary prevention setting.
OBJECTIVE: High Lp(a) (lipoprotein[a]) cause cardiovascular disease (CVD) in a primary prevention setting; however, it is debated whether high Lp(a) lead to recurrent CVD events. We tested the latter hypothesis and estimated the Lp(a)-lowering needed for 5 years to reduce CVD events in a secondary prevention setting. Approach and Results: From the CGPS (Copenhagen General Population Study; 2003-2015) of 58 527 individuals with measurements of Lp(a), 2527 aged 20 to 79 with a history of CVD were studied. The primary end point was major adverse cardiovascular event (MACE). We also studied 1115 individuals with CVD from the CCHS (Copenhagen City Heart Study; 1991-1994) and the CIHDS (Copenhagen Ischemic Heart Disease Study; 1991-1993). During a median follow-up of 5 years (range, 0-13), 493 individuals (20%) experienced a MACE in the CGPS. MACE incidence rates per 1000 person-years were 29 (95% CI, 25-34) for individuals with Lp(a)<10 mg/dL, 35 (30-41) for 10 to 49 mg/dL, 42 (34-51) for 50 to 99 mg/dL, and 54 (42-70) for ≥100 mg/dL. Compared with individuals with Lp(a)<10 mg/dL (18 nmol/L), the multifactorially adjusted MACE incidence rate ratios were 1.28 (95% CI, 1.03-1.58) for 10 to 49 mg/dL (18-104 nmol/L), 1.44 (1.12-1.85) for 50 to 99 mg/dL (105-213 nmol/L), and 2.14 (1.57-2.92) for ≥100 mg/dL (214 nmol/L). Independent confirmation was obtained in individuals from the CCHS and CIHDS. To achieve 20% and 40% MACE risk reduction in secondary prevention, we estimated that plasma Lp(a) should be lowered by 50 mg/dL (95% CI, 27-138; 105 nmol/L [55-297]) and 99 mg/dL (95% CI, 54-273; 212 nmol/L [114-592]) for 5 years. CONCLUSIONS: High concentrations of Lp(a) are associated with high risk of recurrent CVD in individuals from the general population. This study suggests that Lp(a)-lowering by 50 mg/dL (105 nmol/L) short-term (ie, 5 years) may reduce CVD by 20% in a secondary prevention setting.
Entities:
Keywords:
atherosclerosis; cardiovascular disease; cholesterol; population secondary prevention
Authors: Michael J Koren; Monica Florio; Patrick Maurice Moriarty; Seth J Baum; Joel Neutel; Martha Hernandez-Illas; Howard S Weintraub; Helina Kassahun; Stacey Melquist; Tracy Varrieur; Saptarsi M Haldar; Winnie Sohn; Huei Wang; Mary Elliott-Davey; Brooke M Rock; Tao Pei; Oliver Homann; Jennifer Hellawell; Gerald F Watts Journal: Nat Med Date: 2022-01-13 Impact factor: 87.241
Authors: Steven E Nissen; Kathy Wolski; Leslie Cho; Stephen J Nicholls; John Kastelein; Eran Leitersdorf; Ulf Landmesser; Michael Blaha; A Michael Lincoff; Ryuichi Morishita; Sotirios Tsimikas; Junhao Liu; Brian Manning; Plamen Kozlovski; Anastasia Lesogor; Tom Thuren; Taro Shibasaki; Florin Matei; Fábio Serra Silveira; Andreas Meunch; Aysha Bada; Vinod Vijan; Niels Eske Bruun; Borge G Nordestgaard Journal: Open Heart Date: 2022-10
Authors: Ahmed H Mujamammi; Yousef M Alluhaymid; Mohammed G Alshibani; Fawzan Y Alotaibi; Khalid M Alzahrani; Abdulmajeed B Alotaibi; Ahmed A Almasabi; Essa M Sabi Journal: J Family Med Prim Care Date: 2020-06-30
Authors: Anindita Chakraborty; Jing Pang; Dick C Chan; Wendy Barnett; Ann Marie Woodward; Mary Vorster; Gerald F Watts Journal: Clin Cardiol Date: 2021-05-06 Impact factor: 3.287
Authors: Aniruddh P Patel; Minxian Wang (汪敏先); James P Pirruccello; Patrick T Ellinor; Kenney Ng; Sekar Kathiresan; Amit V Khera Journal: Arterioscler Thromb Vasc Biol Date: 2020-10-29 Impact factor: 8.311